ELIC Stock Overview
A clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Elicera Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.75 |
| 52 Week High | SEK 5.80 |
| 52 Week Low | SEK 0.85 |
| Beta | -0.42 |
| 1 Month Change | 3.24% |
| 3 Month Change | 16.67% |
| 1 Year Change | -61.62% |
| 3 Year Change | -65.14% |
| 5 Year Change | n/a |
| Change since IPO | -71.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELIC | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -0.3% | 2.3% | 0.7% |
| 1Y | -61.6% | 15.6% | 4.5% |
Return vs Industry: ELIC underperformed the Swedish Biotechs industry which returned 12.2% over the past year.
Return vs Market: ELIC underperformed the Swedish Market which returned 3.7% over the past year.
Price Volatility
| ELIC volatility | |
|---|---|
| ELIC Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.5% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ELIC's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ELIC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 2 | Jamal El-Mosleh | www.elicera.com |
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors.
Elicera Therapeutics AB (publ) Fundamentals Summary
| ELIC fundamental statistics | |
|---|---|
| Market cap | SEK 61.41m |
| Earnings (TTM) | -SEK 18.26m |
| Revenue (TTM) | SEK 4.29m |
14.3x
P/S Ratio-3.4x
P/E RatioIs ELIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELIC income statement (TTM) | |
|---|---|
| Revenue | SEK 4.29m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 4.29m |
| Other Expenses | SEK 22.54m |
| Earnings | -SEK 18.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 100.00% |
| Net Profit Margin | -426.04% |
| Debt/Equity Ratio | 0% |
How did ELIC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 05:31 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Elicera Therapeutics AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maria Karlsson Osipova | Penser Access |
| Fredrik Thor | Redeye |